Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review

Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.

• Publication year

  2017

• Venue

  Case Reports in Hematology

• Publication date

  2017-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2017/9561013PMID 29090101PMCID 5635466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol

  2019cited by this paper
• Refractory plasmablastic lymphoma—a review of treatment options beyond standard therapy

  2017cited by this paper
• Plasmablastic lymphoma

  2017cited by this paper
• Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma

  2016cited by this paper
• Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

  2016cited by this paper
• Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.

  2016cited by this paper
• Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience.

  2015cited by this paper
• Survival of AIDS‐related diffuse large B‐cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort

  2015cited by this paper
• Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

  2015cited by this paper
• Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma

  2015cited by this paper
• Hematopoietic cell transplantation for plasmablastic lymphoma: a review.

  2014cited by this paper
• Treatment of HIV-associated plasmablastic lymphoma: A single-center experience with 25 patients.

  2014cited by this paper
• Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia.

  2013cited by this paper
• PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

  2013cited by this paper
• Human immunodeficiency virus‐associated plasmablastic lymphoma

  2012cited by this paper
• HIV-negative plasmablastic lymphoma: not in the mouth.

  2011cited by this paper
• Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review.

  2011cited by this paper
• Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.

  2010cited by this paper
• Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

  2009cited by this paper
• Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma

  2009cited by this paper
• HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

  2008cited by this paper
• Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS

  2006cited by this paper
• Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.

  2004cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.

  2002cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.

  1997cited by this paper
• Book Reviews

  1893cited by this paper

• Sinonasal Plasmablastic Lymphoma: A Systematic Review

  2024cites this paper
• Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review

  2021cites this paper
• Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis

  2019cites this paper